Citations (59)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Qian Zeng, Yuanlong Zhong & Xiqiu Yu. (2023) Meta-analysis of the efficacy and safety of sevelamer as hyperphosphatemia therapy for hemodialysis patients. Renal Failure 45:1.
Read now
Read now
Valeria Cernaro, Sebastiano Calimeri, Alfredo Laudani & Domenico Santoro. (2020) Clinical Evaluation of the Safety, Efficacy and Tolerability of Lanthanum Carbonate in the Management of Hyperphosphatemia in Patients with End-Stage Renal Disease. Therapeutics and Clinical Risk Management 16, pages 871-880.
Read now
Read now
Jinshyun Ruth Wu-Wong & Masahide Mizobuchi. (2014) Is there a need for new phosphate binders to treat phosphate imbalance associated with chronic kidney disease?. Expert Opinion on Investigational Drugs 23:11, pages 1465-1475.
Read now
Read now
Takashi Shigematsu, Yuri Nakashima, Masaki Ohya, Koichi Tatsuta, Daisuke Koreeda, Wataru Yoshimoto, Shintaro Yamanaka, Toshifumi Sakaguchi, Yoshiyuki Hanba, Toru Mima & Shigeo Negi. (2012) The management of hyperphosphatemia by lanthanum carbonate in chronic kidney disease patients. International Journal of Nephrology and Renovascular Disease 5, pages 81-89.
Read now
Read now
Stephen J.P. Damment. (2011) Pharmacology of the Phosphate Binder, Lanthanum Carbonate. Renal Failure 33:2, pages 217-224.
Read now
Read now
Patrick Biggar & Markus Ketteler. (2010) Sevelamer carbonate for the treatment of hyperphosphatemia in patients with kidney failure (CKD III – V). Expert Opinion on Pharmacotherapy 11:16, pages 2739-2750.
Read now
Read now
Veerle P Persy, Geert J Behets, Marc E De Broe & Patrick C D’Haese. (2009) Management of hyperphosphatemia in patients with end-stage renal disease: focus on lanthanum carbonate. International Journal of Nephrology and Renovascular Disease 2, pages 1-8.
Read now
Read now
Articles from other publishers (52)
Hsiao-Tien Chen, Kuo-Chuan Hung, Chin-Wei Hsu, Jui-Yi Chen, Chien-Cheng Liu, I-Wen Chen & Cheuk-Kwan Sun. (2023) The efficacy and safety of cuttlebone for lowering serum phosphate in patients with end-stage renal disease: a meta-analysis of randomized controlled trials. Frontiers in Pharmacology 14.
Crossref
Crossref
Evgeny Shutov & Natalia Filatova. 2022. Multidisciplinary Experiences in Renal Replacement Therapy. Multidisciplinary Experiences in Renal Replacement Therapy.
Jelle Vekeman, Javier Torres, Cristina Eugenia David, Els Van de Perre, Karl Martin Wissing, Emmanuel Letavernier, Dominique Bazin, Michel Daudon, Agnieszka Pozdzik & Frederik Tielens. (2021) In Search of an Efficient Complexing Agent for Oxalates and Phosphates: A Quantum Chemical Study. Nanomaterials 11:7, pages 1763.
Crossref
Crossref
Qimeng Zhang, Mingzheng Wang, Guangqin Mu, Haotian Ren, Congshuang He, Qian Xie, Quanxiao Liu, Jigang Wang & Ruitao Cha. (2021) Adsorptivity of cationic cellulose nanocrystals for phosphate and its application in hyperphosphatemia therapy. Carbohydrate Polymers 255, pages 117335.
Crossref
Crossref
Annabel Biruete, Kathleen M. Hill Gallant, Stephen R. Lindemann, Gretchen N. Wiese, Neal X. Chen & Sharon M. Moe. (2020) Phosphate Binders and Nonphosphate Effects in the Gastrointestinal Tract. Journal of Renal Nutrition 30:1, pages 4-10.
Crossref
Crossref
Fellipe A. T. de Figueiredo, Roberta C. Shimano, Edilson Ervolino, Dimitrius L. Pitol, Raquel F. Gerlach & Joao Paulo M. Issa. (2019) Doxycycline reduces osteopenia in female rats. Scientific Reports 9:1.
Crossref
Crossref
Ezequiel Bellorin-Font, George Vasquez-Rios & Kevin J. Martin. (2019) Controversies in the Management of Secondary Hyperparathyroidism in Chronic Kidney Disease. Current Osteoporosis Reports 17:5, pages 333-342.
Crossref
Crossref
Fellype Carvalho Barreto, Daniela Veit Barreto, Ziad A. Massy & Tilman B. Drüeke. (2019) Strategies for Phosphate Control in Patients With CKD. Kidney International Reports 4:8, pages 1043-1056.
Crossref
Crossref
Kamyar Kalantar-Zadeh, Vidhya Parameswaran, Linda H. Ficociello, Ludmila Anderson, Norma J. Ofsthun, Christopher Kwoh, Claudy Mullon, Robert J. Kossmann & Daniel W. Coyne. (2018) Real-World Scenario Improvements in Serum Phosphorus Levels and Pill Burden in Peritoneal Dialysis Patients Treated with Sucroferric Oxyhydroxide. American Journal of Nephrology 47:3, pages 153-161.
Crossref
Crossref
Alastair J Hutchison, Rosamund J Wilson, Svetlana Garafola & John Brian Copley. (2016) Lanthanum carbonate: safety data after 10 years. Nephrology 21:12, pages 987-994.
Crossref
Crossref
Lisa Gutekunst. (2016) An Update on Phosphate Binders: A Dietitian's Perspective. Journal of Renal Nutrition 26:4, pages 209-218.
Crossref
Crossref
Jorge B. Cannata-Andía & Kevin J. Martin. (2016) The challenge of controlling phosphorus in chronic kidney disease. Nephrology Dialysis Transplantation 31:4, pages 541-547.
Crossref
Crossref
Yongsheng Yang, Adil Mohammad, Robert T. Berendt, Alan Carlin, Mansoor A. Khan & Patrick J. Faustino. (2016) Evaluation of the In Vitro Efficacy of Sevelamer Hydrochloride and Sevelamer Carbonate. Journal of Pharmaceutical Sciences 105:2, pages 864-875.
Crossref
Crossref
. 2016. Meyler's Side Effects of Drugs. Meyler's Side Effects of Drugs
470
472
.
Blanca Gros, Antonio Galán, Emilio González-Parra, Jose A Herrero, Maria Echave, Stefan Vegter, Keith Tolley & Itziar Oyagüez. (2015) Cost effectiveness of lanthanum carbonate in chronic kidney disease patients in Spain before and during dialysis. Health Economics Review 5:1.
Crossref
Crossref
Florian S. Gutzwiller, Alena M. Pfeil, Zanfina Ademi, Patricia R. Blank, Peter G. Braunhofer, Thomas D. Szucs & Matthias Schwenkglenks. (2015) Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland. PharmacoEconomics 33:12, pages 1311-1324.
Crossref
Crossref
Fateme Shamekhi Amiri. (2015) Contemporary management of phosphorus retention in chronic kidney disease: a review. Clinical and Experimental Nephrology 19:6, pages 985-999.
Crossref
Crossref
Z. Asemi, P. Saneei, S.-S. Sabihi, A. Feizi & A. Esmaillzadeh. (2015) Total, dietary, and supplemental calcium intake and mortality from all-causes, cardiovascular disease, and cancer: A meta-analysis of observational studies. Nutrition, Metabolism and Cardiovascular Diseases 25:7, pages 623-634.
Crossref
Crossref
Elizabeth A. Bobeck, Erica M. Hellestad, Jordan M. Sand, Michelle L. Piccione, Jeff W. Bishop, Christian Helvig, Martin Petkovich & Mark E. Cook. (2015) Oral peptide specific egg antibody to intestinal sodium-dependent phosphate co-transporter-2b is effective at altering phosphate transport in vitro and in vivo. Poultry Science 94:6, pages 1128-1137.
Crossref
Crossref
T.M.-H. Nguyen, R.H. Müller, M. Taupitz, J. Schnorr, B. Hamm & S. Wagner. (2015) Novel oral phosphate binder with nanocrystalline maghemite-phosphate binding capacity and pH effect. International Journal of Pharmaceutics 482:1-2, pages 21-26.
Crossref
Crossref
Caroline M. Perry & Greg L. Plosker. (2014) Sevelamer Carbonate: A Review in Hyperphosphataemia in Adults with Chronic Kidney Disease. Drugs 74:7, pages 771-792.
Crossref
Crossref
Xiaojian Jiang, Yongsheng Yang & Ethan Stier. 2014. FDA Bioequivalence Standards. FDA Bioequivalence Standards
297
334
.
Jing Xu, Yi-Xiang Zhang, Xue-Qing Yu, Zhi-Hong Liu, Li-Ning Wang, Jiang-Hua Chen, Ya-Ping Fan, Zhao-Hui Ni, Mei Wang, Fa-Huan Yuan, Guo-Hua Ding, Xiang-Mei Chen, Ai-Ping Zhang & Chang-Lin Mei. (2013) Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in mainland China. BMC Nephrology 14:1.
Crossref
Crossref
Zaw Thet, Aung Ko WIN, Eugenie Pedagogos, Jennifer Beavis, Sandra Crikis & Craig Nelson. (2013) Differential effects of phosphate binders on pre-dialysis serum bicarbonate in end-stage kidney disease patients on maintenance haemodialysis. BMC Nephrology 14:1.
Crossref
Crossref
Adrian Covic & Anjay Rastogi. (2013) Hyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherence. BMC Nephrology 14:1.
Crossref
Crossref
Tsutomu Sakurada, Daisuke Oishi, Yugo Shibagaki, Takashi Yasuda & Kenjiro Kimura. (2013) Efficacy of oral powder compared with chewable tablets for lanthanum carbonate administration in hemodialysis patients. Hemodialysis International 17, pages S2-S6.
Crossref
Crossref
Junko Nakaki, Shinichi Yamaguchi, Yuichi Torii, Atsushi Inoue, Satoshi Minakami, Takami Kanno, Masanori Murakami, Masahiro Tsuzuki, Hidenori Mochizuki, Kazuharu Suyama & Mitsuko Miyamoto. (2013) Effect of fatty acids on the phosphate binding of TRK-390, a novel, highly selective phosphate-binding polymer. European Journal of Pharmacology 714:1-3, pages 312-317.
Crossref
Crossref
Michiya Ohno, Hiroshige Ohashi, Hiroshi Oda, Haruko Yokoyama, Miho Okada, Mayu Nagaya, Kumiko Izumi, Hitomi Ito & Shuji Katoh. (2013) Lanthanum Carbonate for Hyperphosphatemia in Patients on Peritoneal Dialysis. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis 33:3, pages 297-303.
Crossref
Crossref
Yongsheng Yang, Srikant Bykadi, Alan S. Carlin, Rakhi B. Shah, Lawrence X. Yu & Mansoor A. khan. (2013) Comparative Evaluation of the In Vitro Efficacy of Lanthanum Carbonate Chewable Tablets. Journal of Pharmaceutical Sciences 102:4, pages 1370-1381.
Crossref
Crossref
Elizabeth A. Bobeck, Katie M. Meyer, Christian Helvig, Martin Petkovich & Mark E. Cook. (2013) Sevelamer Hydrochloride Binds Phosphate Released from Phytate in Chicks Fed 1α-Hydroxy Cholecalciferol. Journal of Renal Nutrition 23:1, pages 21-27.
Crossref
Crossref
Atsushi InoueSatoshi MinakamiTakami KannoKazuharu Suyama. (2012) Highly Selective and Low-swelling Phosphate-binding Polymer for Hyperphosphatemia Therapy. Chemistry Letters 41:9, pages 932-933.
Crossref
Crossref
Stefan Vegter, Keith Tolley, Michael S. Keith, Charmaine E. Lok, Steven D. Soroka & A. Ross Morton. (2012) Cost-Effectiveness of Lanthanum Carbonate in the Treatment of Hyperphosphatemia in Dialysis Patients: A Canadian Payer Perspective. Clinical Therapeutics 34:7, pages 1531-1543.
Crossref
Crossref
Haesuk Park, Karen L. Rascati, Michael S. Keith, Paul Hodgkins, Michael Smyth, David Goldsmith & Ron Akehurst. (2011) Cost-Effectiveness of Lanthanum Carbonate versus Sevelamer Hydrochloride for the Treatment of Hyperphosphatemia in Patients with End-Stage Renal Disease: A US Payer Perspective. Value in Health 14:8, pages 1002-1009.
Crossref
Crossref
Stefan Vegter, Keith Tolley, Michael S. Keith & Maarten J. Postma. (2011) Cost-Effectiveness of Lanthanum Carbonate in the Treatment of Hyperphosphatemia in Chronic Kidney Disease Before and During Dialysis. Value in Health 14:6, pages 852-858.
Crossref
Crossref
María Luisa González Casaús, Emilio González Parra, Víctor Manuel Navas Serrano, Carolina Gracia Iguacel, Pilar de Ribera Pieras & Jesús Egido de Los Ríos. (2011) Tratamiento de la hiperfosfatemia asociada a la enfermedad renal crónica con carbonato de lantano. Nuevas evidencias. Diálisis y Trasplante 32:3, pages 102-107.
Crossref
Crossref
Alexandra Gramowski, Konstantin Jügelt, Olaf H.-U. Schröder, Dieter G. Weiss & Steffen Mitzner. (2011) Acute Functional Neurotoxicity of Lanthanum(III) in Primary Cortical Networks. Toxicological Sciences 120:1, pages 173-183.
Crossref
Crossref
Vassilis Filiopoulos, Ioannis Koutis, Sofia Trompouki, Dimitrios Hadjiyannakos, Dimitrios Lazarou & Dimosthenis Vlassopoulos. (2011) Lanthanum Carbonate Versus Sevelamer Hydrochloride: Improvement of Metabolic Acidosis and Hyperkalemia in Hemodialysis Patients. Therapeutic Apheresis and Dialysis 15:1, pages 20-27.
Crossref
Crossref
Stuart M Sprague. (2010) Renal bone disease. Current Opinion in Endocrinology, Diabetes & Obesity 17:6, pages 535-539.
Crossref
Crossref
Wing Lam Winnie Chan, Karen Rounsley, Emma Chapman, Katherine Collings, Clare Dale, Susan De Waal, Vandhana Patel, Jill Tanner, Elaine Turner, Jason Moore & Richard Borrows. (2010) Lanthanum Carbonate Is an Effective Hypophosphatemic Agent for Hemodialysis Patients Intolerant of Other Phosphate Binders. Journal of Renal Nutrition 20:4, pages 270-277.
Crossref
Crossref
Franz Jakob & Peter Jehle. 2010. Praktische Endokrinologie. Praktische Endokrinologie
303
309
.
M. Sundaram, A. Mohapatra & G. T. John. (2009) 'Stone'-blindness. Clinical Kidney Journal 2:6, pages 493-494.
Crossref
Crossref
Monique P. Curran & Dean M. Robinson. (2009) Lanthanum Carbonate. Drugs 69:16, pages 2329-2349.
Crossref
Crossref
Sankar D. Navaneethan, Suetonia C. Palmer, Jonathan C. Craig, Grahame J. Elder & Giovanni F.M. Strippoli. (2009) Benefits and Harms of Phosphate Binders in CKD: A Systematic Review of Randomized Controlled Trials. American Journal of Kidney Diseases 54:4, pages 619-637.
Crossref
Crossref
Ye-Bo Zhou, Shao-Ju Jin, Yan Cai, Xu Teng, Li Chen, Chao-Shu Tang & Yong-Fen Qi. (2009) Lanthanum Acetate Inhibits Vascular Calcification Induced by Vitamin D3 Plus Nicotine in Rats. Experimental Biology and Medicine 234:8, pages 908-917.
Crossref
Crossref
. (2009) References. Kidney International 76, pages S121-S130.
Crossref
Crossref
. (2009) Chapter 4.1: Treatment of CKD–MBD targeted at lowering high serum phosphorus and maintaining serum calcium. Kidney International 76, pages S50-S99.
Crossref
Crossref
Ashwini B. Pai & Brian M. Shepler. (2012) Comparison of Sevelamer Hydrochloride and Sevelamer Carbonate: Risk of Metabolic Acidosis and Clinical Implications. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 29:5, pages 554-561.
Crossref
Crossref
Monique Elseviers & Jean-Yves De Vos. (2009) THE USE OF PHOSPHATE BINDERS: DATA FROM CONTRIBUTORS TO THE EUROPEAN PRACTICE DATABASE. Journal of Renal Care 35, pages 14-18.
Crossref
Crossref
G.B. van der Voet & J.A. Centeno. 2009.
383
397
.
. (2008) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 17:7.
Crossref
Crossref
Víctor Manuel Navas-Serrano. (2008) Carbonato de lantano como tratamiento de la hiperfosfatemia de la enfermedad renal crónica. Diálisis y Trasplante 29:2, pages 67-71.
Crossref
Crossref
Stephen J P Damment & Michael Pennick. (2008) Clinical Pharmacokinetics of the Phosphate Binder Lanthanum Carbonate. Clinical Pharmacokinetics 47:9, pages 553-563.
Crossref
Crossref